MedTrace Logo

Brain Networks Implicated in Lifelong Premature Ejaculation Patients

NCT04850703 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2023-04-12

No results posted yet for this study

Summary

Using Brain Mapping and Cognitive ERPs, the investigatos have searched for a Brain Networks involved during Inhibitory Control in Lifelong Premature Ejaculation (LPE) participants. The investigators have designed a clinical trial comparing placebo with tDCS and blacebo group against Dapoxetine, studying the effects on LPE, as well as side effects and their medium and long-term duration.

Conditions

  • Premature Ejaculation
  • Sexual Dysfunction

Interventions

DEVICE

Transcranial Radom Noise Stimulation

tRNS against Dapoxetine in LPE patients

DRUG

Take Dapoxetine

Dapoxetine against tRNS in LPE patients

COMBINATION_PRODUCT

Comparation EEG changes between Sham Group against tRNS and Dapoxetin participants

Compare EEG parameters like Theta Rhythm and Coherence between three groups of participants: sham, tRNS participants and Dapoxetine participants groups.

DIAGNOSTIC_TEST

Compare LPE EEG endophenotype between participants and healthy controls

Define as precisely as possible the electrophysiological endophenotype of Longlife Premature Ejaculation, using healthy humans who do not express the LPE EEG endophenotype

Sponsors & Collaborators

  • Dr. Alejandro Molina Cabeza

    collaborator UNKNOWN

  • Susana Ferrandis Martinez

    collaborator UNKNOWN

  • Moises Domingo

    lead OTHER

Principal Investigators

  • Alejandro Molina Cabeza, MD · Sexual Salud Valclinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-02
Primary Completion
2022-05-21
Completion
2023-02-04

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04850703 on ClinicalTrials.gov